SEC Form 15-12G filed by Elevation Oncology Inc.
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13
AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
001-40523
Commission File Number
(Exact name of registrant as specified in its charter)
101 Federal Street, Suite 1900
Boston, MA 02110
(716) 371-1125
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, $0.0001 par value per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
☒
|
|
Rule 12g-4(a)(2)
|
☐
|
|
Rule 12h-3(b)(1)(i)
|
☒
|
|
Rule 12h-3(b)(1)(ii)
|
☐
|
|
Rule 15d-6
|
☐
|
|
Rule 15d-22(b)
|
☐
|
|
Approximate number of holders of record as of the certification or notice date:
|
One
|
Pursuant to the requirements of the Securities Exchange Act of 1934, Elevation Oncology, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
|
Date: August 4, 2025
|
ELEVATION ONCOLOGY, INC.
|
|
|
By:
|
/s/ Michael Hearne | |
|
Name: Michael Hearne
|
||
|
Title: Chief Financial Officer
|
||